Journal
JOURNAL OF CELL COMMUNICATION AND SIGNALING
Volume 9, Issue 1, Pages 101-102Publisher
SPRINGER
DOI: 10.1007/s12079-015-0283-9
Keywords
CD47; Tumor-initiating cells; Cathepsin-S; NF kappa B; Chemoresistance
Categories
Ask authors/readers for more resources
CD47 is a signaling receptor for the matricellular protein thrombospondin-1 and a counter-receptor for signal regulatory protein-alpha (SIRP alpha) on macrophages. Following its initial discovery in 1992 as a cell surface protein that is overexpressed by ovarian carcinoma, elevated CD47 expression has emerged as a negative prognostic factor for a variety of cancers. CD47 is also a potential therapeutic target based on the ability of CD47 blockade to cause regression of tumors in mice, and a humanized CD47 antibody has recently entered phase I clinical trials. CD47 blockade may control tumor growth by inhibiting thrombospondin-1 signaling or by preventing inhibitory SIRP alpha signaling in tumor-associated macrophages. A recent publication by Lee et al. (Hepatology 60:179-191, 2014) provides evidence that blocking CD47 signaling specifically depletes tumor-initiating stem cells in hepatocellular carcinoma and implicates cathepsin-S/protease-activated receptor-2 signaling in mediating this therapeutic response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available